Reevaluating the Concept of Autologous Graft-Versus-Host Disease

Overview

The term 'auto-GVHD' describes a syndrome resembling acute GVHD occurring after autologous or syngeneic transplants, but its etiological basis remains unclear. Diagnostic challenges arise due to overlapping clinical, laboratory, and histological features with other conditions, and the lack of definitive biomarkers or criteria to confirm true GVHD in genetically identical donor-recipient pairs.

Background

Graft-versus-host disease (GVHD) traditionally occurs when donor immune cells attack host tissues following allogeneic transplantation. The concept of auto-GVHD emerged to describe similar clinical and pathological features seen after autologous or syngeneic transplants, where donor and recipient are genetically identical. Historical animal studies demonstrated that GVHD requires genetic disparity and additional factors such as infection state, complicating the interpretation of auto-GVHD. Human diagnosis of acute GVHD relies on clinical, laboratory, and histological criteria, all of which have limitations and significant inter-observer variability.

Data Highlights

Key historical and experimental findings include:

• 1951: Lorenz et al. identified a syndrome in irradiated rodents receiving genetically disparate bone marrow and spleen cells, termed secondary disease.
• 1955: Main and Prehn demonstrated donor immune cells cause secondary disease by recognizing host histocompatibility antigens.
• Jones et al. and van Bekkum et al. showed GVHD development depends on microbiological status of recipient mice.
• Brandon et al. found antibiotic and cyclosporine therapy prevented acute GVHD features in syngeneic transplants.
• Paczesny et al. described a biomarker panel (IL-2Rα, TNF-R1, hepatocyte growth factor, IL-8) associated with acute GVHD but these markers predict inflammation and mortality rather than GVHD specifically.

Key Findings

• The label 'auto-GVHD' implies an immune-mediated attack by graft cells against host antigens, which is difficult to conceptualize in genetically identical transplants.
• Diagnosis of acute GVHD in humans is complicated by variable clinical criteria and significant inter-observer variability.
• Histological features of acute GVHD lack specificity and overlap with changes caused by radiation, drugs, and infections.
• Biomarker panels correlate with inflammation and mortality risk but do not definitively diagnose acute GVHD.
• Animal studies indicate that factors beyond genetic disparity, such as microbiome and immunosuppression, influence GVHD development.
• Current diagnostic approaches cannot reliably determine sensitivity or specificity for acute GVHD due to uncertain case definitions.

Clinical Implications

Clinicians should exercise caution when diagnosing auto-GVHD, recognizing the limitations of current clinical, laboratory, and histological criteria. A diagnosis of acute GVHD after autologous or syngeneic transplantation should consider alternative causes such as drug toxicity, infection, or radiation effects. Biomarker panels may aid in assessing inflammatory status but are not definitive for GVHD diagnosis.

Conclusion

The concept of auto-GVHD remains controversial and diagnostically challenging due to unclear pathogenesis and overlapping features with other conditions. Improved understanding and more specific diagnostic tools are needed to clarify this entity and guide appropriate management.

References

1. Lorenz et al. 1951 -- Secondary disease in irradiated rodents
2. Main and Prehn 1955 -- Donor immune cells cause secondary disease
3. Jones et al. and van Bekkum et al. -- Influence of microbiome on GVHD
4. Brandon et al. -- Antibiotic and cyclosporine effects on syngeneic transplant GVHD
5. Paczesny et al. -- Biomarker panel associated with acute GVHD